" class="no-js "lang="en-US"> Ajit Shankaranarayanan - Medtech Alert
Tuesday, October 07, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ajit Shankaranarayanan

Ajit Shankaranarayanan

About Ajit Shankaranarayanan

Ajit received his Ph.D. in Biomedical Engineering from Case Western Reserve University. Before Subtle, Ajit was Chief Operating Officer at HealthLytix and spent 16 years with GE Healthcare as the Global Manager for Neurology in the MR division where he guided the overall vision and goals of GE MR.

Related Story

Artificial Intelligence

 Subtle Medical Announces Partnership Expansion With Incepto | Pharmtech Focus

Subtle Medical Announces Partnership Expansion With Incepto

July 18 2022

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced […]